XML 106 R61.htm IDEA: XBRL DOCUMENT
v3.23.1

COLLABORATION ARRANGEMENTS (Details) | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Mar. 31, 2022 USD ($) | Apr. 30, 2019 item | Dec. 31, 2018 USD ($) | Dec. 31, 2018 CNY (¥) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 CNY (¥) | Dec. 31, 2020 USD ($) | Dec. 31, 2020 CNY (¥) | Dec. 31, 2019 CNY (¥) | Aug. 31, 2022 USD ($) | Apr. 30, 2022 USD ($) | Feb. 28, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | $ 9,292,724 | $ 10,175,258 |  | $ 700,913 |  |  |  |  |
Accounts receivable, net |  |  |  |  |  | 3,000,000 |  |  |  |  |  |  |
Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment received |  |  | $ 1,511,168 | ¥ 10,000,000 |  |  |  |  |  |  |  |  |
Agreed period for not to grant rights associated with antibodies to third parties |  |  | 3 years | 3 years |  |  |  |  |  |  |  |  |
Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment received |  |  |  |  |  |  |  | 573,378 | ¥ 4,000,000 |  |  |  |
Agreed period for not to grant rights associated with antibodies to third parties |  |  |  |  | 3 years |  |  |  |  |  |  |  |
Revenues |  |  |  |  | $ 0 | 1,240,022 | ¥ 8,000,000 |  | ¥ 0 | ¥ 0 |  |  |
Milestone fee received |  |  |  |  |  | 620,011 | ¥ 4,000,000 |  |  |  |  |  |
ADCT Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  | 225,000 |  | 225,000 |  |  |  |  |
Maximum number of selected targets, agreed for generation of antibodies | item |  | 2 |  |  |  |  |  |  |  |  |  |  |
Minimum threshold written notice period for termination of agreement |  |  |  |  | 30 days |  |  |  |  |  |  |  |
Period for reservation of target right |  |  |  |  | 1 year |  |  |  |  |  |  |  |
Other income |  |  |  |  |  |  |  | $ 100,000 |  |  |  |  |
Exelixis Inc Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment received |  |  |  |  | $ 1,100,000 | 11,000,000 |  |  |  |  |  |  |
Revenues |  |  |  |  | 0 | 8,500,000 |  |  |  |  |  |  |
Payment of upfront-refundable fee |  |  |  |  |  |  |  |  |  |  |  | $ 1,100,000 | $ 11,000,000
Milestone payments receivable based on development and regulatory milestones |  |  |  |  |  |  |  |  |  |  |  |  | 127,500,000
Milestone payments receivable based on sales |  |  |  |  |  |  |  |  |  |  |  |  | $ 262,500,000
Accounts receivable, net |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |
ADCT Material Transfer and Option Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | 300,000 |  |  |  |  |  |  |  |
Payment of upfront-refundable fee |  |  |  |  |  |  |  |  |  |  | $ 300,000 |  |
Sanofi Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment received | $ 17,500,000 |  |  |  | 17,500,000 |  |  |  |  |  |  |  |
Revenues |  |  |  |  | $ 8,992,724 |  |  |  |  |  |  |  |
Milestone payments receivable based on development and regulatory milestones | 173,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments receivable based on sales | $ 450,000,000 |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The agreed period for not to grant rights associated with antibodies to third parties. + References No definition available. + Details
Name: | adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties
Namespace Prefix: | adag_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from milestone payments received in collaborative arrangement. + References No definition available. + Details
Name: | adag_CollaborativeArrangementMilestonePaymentReceived
Namespace Prefix: | adag_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront cash payment receivable. + References No definition available. + Details
Name: | adag_CollaborativeArrangementUpfrontCashPaymentReceivable
Namespace Prefix: | adag_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash inflow from upfront cash received in collaborative arrangement. + References No definition available. + Details
Name: | adag_CollaborativeArrangementUpfrontCashPaymentReceived
Namespace Prefix: | adag_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum number of selected targets, agreed for generation of antibodies. + References No definition available. + Details
Name: | adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies
Namespace Prefix: | adag_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments receivable upon achieving certain development and regulatory approval milestones. + References No definition available. + Details
Name: | adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones
Namespace Prefix: | adag_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payments conditioned upon achieving sales based milestones. + References No definition available. + Details
Name: | adag_MilestonePaymentsReceivableSalesBasedMilestones
Namespace Prefix: | adag_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The minimum threshold written notice period for termination of agreement. + References No definition available. + Details
Name: | adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement
Namespace Prefix: | adag_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period for reservation of target right. + References No definition available. + Details
Name: | adag_PeriodForReservationOfTargetRight
Namespace Prefix: | adag_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue and income classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.4) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details
Name: | us-gaap_OtherIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adag_AdctCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adag_ExelixisIncAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adag_AdctMaterialTransferAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adag_SanofiAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |